Source comparison
Thymosin Alpha-1 Dosage Protocol: Research Comparison
Low-Dose Adjunct 0.8mg 1.6mg Twice weekly (Mon/Thu) Hepatitis B/C antiviral support +8–12% from baseline Effective for mild immune support—best when combined with antiviral therapy. Lowest cost per cycle. Standard Therapeutic 3.2mg Twice weekly (Tue/Fri) Cance
This comparison does not assign a generated winner or score.
- Low-Dose Adjunct
- 0.8mg
- 1.6mg
- Twice weekly (Mon/Thu)
- Hepatitis B/C antiviral support
- +8–12% from baseline
- Effective for mild immune support—best when combined with antiviral therapy. Lowest cost per cycle.
- Standard Therapeutic
- 3.2mg
- Twice weekly (Tue/Fri)
- Cancer immunotherapy, chronic fatigue, post-transplant recovery
- +25–35% IL-2 receptor expression
- Most common protocol in published literature. Balances efficacy with minimal injection-site reactions.
- High-Dose Intervention
- 3.2–6.4mg
- 6.4–12.8mg
- Severe immune dysfunction, HIV, sepsis recovery
- +120 cells/μL in patients <200 baseline
- Reserved for severe cases. Higher incidence of mild erythema at injection sites (15–20%). Demonstrates strongest immune reconstitution.